Monitoring of Risedronate by biochemical bone markers in clinical practice.
No Thumbnail Available
Date
2005-10-16
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.
Description
Chotmaihet Thangphaet.
Keywords
Citation
Bunyaratavej N. Monitoring of Risedronate by biochemical bone markers in clinical practice. Journal of the Medical Association of Thailand. 2005 Oct; 88(suppl 5): S34-6